VivoSeq
Oncology

Myelodysplastic/myeloproliferative Neoplasm

10

Pipeline Programs↗

1

Active Trials↗

7

Companies Involved↗

Myelodysplastic/Myeloproliferative Neoplasm is an early-stage landscape with 10 programs across 7 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Taiho Oncology, Inc., AbbVie. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

0/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1Taiho Oncology, Inc. logo

Taiho Oncology, Inc.

2 programs

Phase 2AbbVie logo

AbbVie

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2Incyte logo

Incyte

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

8 of 10 classified programs — the dominant modality here.

20%ALL OTHERSProtein / enzyme220%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

4

clinical trials

Unknown status1 · 25%
Terminated1 · 25%
Withdrawn1 · 25%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT05282719·33 enrolled
Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts
Terminated·MMayo Clinic·Phase 2·NCT05005182·3 enrolled
Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms
Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT06284460
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT04493138·58 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)